SMi Source lesson Oncology: Head and Neck has the following microlearning topics
1. Learning Objectives
2. Introduction: Head and Neck Cancers
3. Introduction: Treatment for Head and Neck Cancers
4. Introduction
5. Head and Neck Anatomy
6. Head and Neck Anatomy
7. Cellular Classification: Squamous Cell Carcinoma
8. Cellular Classification: Nasopharyngeal Carcinoma
9. Cellular Classification: Salivary Gland Cancers
10. Cellular Classification: Malignant Salivary Gland Neoplasms
11. Risk Factors: Tobacco
12. Risk Factors: Alcohol and Pathogens
13. Risk Factors: Pathogens HPV
14. Risk Factors: Pathogens, UV Light Occupational and Radiation Exposures
15. Risk Factors: Diet, Oral Hygiene and Inherited Conditions
16. Mechanisms of Disease Development and Progression: Pathogenesis of HNSCC
17. Anatomy and Pathophysiology
18. Anatomy and Pathophysiology
19. Mechanisms of Disease Development and Progression: Immune System Evasion
20. Incidence
21. Epidemiology
22. Clinical Presentation: Signs and Symptoms
23. Clinical Presentation: Physical Examination
24. Clinical Presentation: Staging Investigations
25. Staging
26. Treatment Overview: Head and Neck Cancers
27. Treatment Overview: Status and Goals
28. Treatment Overview: Therapies and Treatment
29. Treatment Overview: Additional Treatment and Surveillance
30. Impact of Disease and Treatment
31. Curative Surgery
32. Radiation Therapy (RT): Treatment of HNSCC
33. Radiation Therapy (RT): Radiation Fractionation, IMRT, Brachytherapy
34. Radiation Therapy (RT): Complications
35. Chemotherapy (CTx): Advantages and Recommendations
36. Chemotherapy (CTx): Concurrent Chemoradiotherapy (CRT), Induction Chemotherapy (IC)
37. Chemotherapy (CTx): Recurrent, Unresectable, and Metastatic Cancer Chemotherapy
38. Chemotherapy (CTx): Toxicities of Treatment, HNSCC Chemotherapy Agents
39. Palliative Therapy
40. Salivary Gland Cancer
41. HPV-Positive HNSCC
42. Protocols
43. NCCN Treatment Guidelines
44. Overview: Investigational Strategies in the Treatment of Head and Neck Cancers
45. Epidermal Growth Factor Receptor (EGFR)
46. Tyrosine Kinase Inhibitors
47. TGF Pathway
48. VEGF
49. c-Kit and HER-2, Carcinoembryonic Antigen (CEA) and Targeted Therapy Clinical Trials for HNSCC
50. Vaccines for HNSCC
51. Evolution of Head and Neck Cancer Treatment
52. Radiotherapy Studies
53. Postoperative Radiotherapy and Chemoradiotherapy
54. Concurrent Chemoradiation Regimens: Standard of Care
55. Concurrent Chemoradiation Regimens: Incidence of Acute Adverse Events
56. Induction Chemotherapy: TAX 232 and TAX 324 Studies
57. Induction Chemotherapy: VA Cooperative and RTOG 91-11 Studies
58. Recurrent Unresectable/Metastatic HNSCC
59. New Targeted Therapies: Molecular Therapies in HNSCC
60. New Targeted Therapies: Targeted Therapies as Single Therapies
61. Salivary Gland Cancer
62. Conclusions: Head and Neck Cancer Epidemiology and Genetics
63. Conclusions: Head and Neck Treatment
